A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2011
11/17/2011	WO2011074006A3 Vaccine composition
11/17/2011	WO2011071916A3 Sr-bi as a predictor of human female infertility and responsiveness to treatment
11/17/2011	WO2011063161A3 Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
11/17/2011	WO2011060272A3 Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
11/17/2011	WO2011044336A3 Human domain antibodies against components of the human insulin-like growth factor (igf) system
11/17/2011	WO2011031317A3 Vaccine for control of trypanosoma cruzi infection and chagas disease
11/17/2011	WO2011006914A3 Antagonists, uses & methods for partially inhibiting tnfr1
11/17/2011	US20110282037 Antibody preparation
11/17/2011	US20110281799 Vascular Endothelial Growth Factor D (VEGF-D) Antibodies and Vectors, and Methods of Uses
11/17/2011	US20110281357 Methods to cause differentiation of T-cells for use in cell therapy
11/17/2011	US20110281292 Compositions and methods for identifying antigens which elicit an immune response
11/17/2011	US20110280949 Microparticles for use in immunogenic compositions
11/17/2011	US20110280934 Increased Expression of Specific Antigens
11/17/2011	US20110280930 Products and methods for stimulating an immune response
11/17/2011	US20110280913 Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders
11/17/2011	US20110280911 Cancer vaccine compositions and methods of using the same
11/17/2011	US20110280910 Novel surface exposed immunoglobulin d-binding protein from moraxella catarrhalis
11/17/2011	US20110280909 Method and system for effecting changes in pigmented tissue
11/17/2011	US20110280908 Multimeric protein toxins to target cells having multiple identifying characteristics
11/17/2011	US20110280907 Method and system for building a phylogeny from genetic sequences and using the same for recommendation of vaccine strain candidates for the influenza virus
11/17/2011	US20110280906 Method for augmenting the immunogenicity of an antigen
11/17/2011	US20110280905 Live attenuated chimeric porcine circovirus vaccine
11/17/2011	US20110280904 Generation of virus-like particles and use as panfilovirus vaccine
11/17/2011	US20110280903 Immunostimulatory combinations
11/17/2011	US20110280901 Diagnosis and treatment of Trypanosoma cruzi infection and chagas disease
11/17/2011	US20110280900 Clostridium chauvoei polypeptide, dna encoding the polypeptide and a vaccine comprising the polypeptide
11/17/2011	US20110280899 Novel Immunogenic Lipopeptides Comprising T-Helper And Cytotoxic T-Lymphocyte (CTL) Epitopes
11/17/2011	US20110280898 Inhbb epitope peptides and vaccines containing the same
11/17/2011	US20110280897 Polypeptides and uses thereof
11/17/2011	US20110280896 Methods and compositions for tumor vaccination and therapy
11/17/2011	US20110280895 IMMUNOTHERAPEUTIC METHOD USING ALLO-CELLS WHICH CO-EXPRESS CD1d AND TARGET ANTIGEN
11/17/2011	US20110280894 Her2/neu specific t cell receptors
11/17/2011	US20110280893 Synthetic lipid a derivative
11/17/2011	US20110280892 Toxin conjugated eph receptor antibodies
11/17/2011	US20110280891 Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
11/17/2011	US20110280890 Prodrugs of cc-1065 analogs
11/17/2011	US20110280889 High affinity t cell receptor and use thereof
11/17/2011	US20110280888 Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
11/17/2011	US20110280887 Methods for diagnosis of cardiovascular disease
11/17/2011	US20110280886 Treating cancer by modulating mnk
11/17/2011	US20110280885 Cancer immunotherapy
11/17/2011	US20110280884 Anti-cd98 antibody
11/17/2011	US20110280883 Fully human anti-epidermal growth factor receptor antibodies
11/17/2011	US20110280882 Leukolectins and uses thereof
11/17/2011	US20110280881 Novel anti-hsp90 monoclonal antibody
11/17/2011	US20110280880 Prevention, treatment and diagnosis of p.gingivalis infection
11/17/2011	US20110280879 Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
11/17/2011	US20110280878 Substance specific to human pd-1
11/17/2011	US20110280877 Inhibition of B7-H1/CD80 interaction and uses thereof
11/17/2011	US20110280876 Mutated netrin - 4, fragments thereof and their use as medicines
11/17/2011	US20110280875 Antibodies which bind human cxcr3
11/17/2011	US20110280874 Modulating angiogenesis
11/17/2011	US20110280873 MCP1-Ig FUSION VARIANTS
11/17/2011	US20110280872 Methods for prevention and treatment of inflammation using anti-chemokine antibodies
11/17/2011	US20110280871 Methods for prevention and treatment of inflammation using anti-chemokine antibodies
11/17/2011	US20110280870 Hepatocyte growth factor receptor antagonists and uses thereof
11/17/2011	US20110280869 Methods of preventing or treating inflammatory or autoimmune disorders by administering cd2 antagonists in combination with other prophylactic or therapeutic agents
11/17/2011	US20110280868 Methods of preventing or treating t cell malignancies by administering anti-cd2 antagonists
11/17/2011	US20110280867 Heterocyclic aspartyl protease inhibitors
11/17/2011	US20110280866 Anti-cd 160 monoclonal antibodies and uses thereof
11/17/2011	US20110280865 Ets-2 Biomarkers for Fibrotic Diseases and Uses Thereof
11/17/2011	US20110280864 Low Viscosity Highly Concentrated Suspensions
11/17/2011	US20110280863 Methods and compositions for the detection and treatment of preeclampsia
11/17/2011	US20110280862 Gep and drug transporter regulation, cancer therapy and prognosis
11/17/2011	US20110280861 Method for mir-125a in promoting hematopoietic stem cell self renewal and expansion
11/17/2011	US20110280860 Pharmaceutical compositions comprising monoterpenes
11/17/2011	US20110280833 Peptides, derivatives and analogs thereof, and methods of using same
11/17/2011	US20110280832 Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
11/17/2011	US20110280831 Combinations comprising methotrexate and dhodh inhibitors
11/17/2011	US20110280830 Albumin Fusion Proteins
11/17/2011	US20110280827 Methods and compositions for treating hematological malignancies
11/17/2011	US20110280813 Neuraminidase inhibitors and uses thereof
11/17/2011	US20110280809 Pdia4, target of cytopiloyne derivatives, for tumor diagnosis and treatment
11/17/2011	US20110280808 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
11/17/2011	US20110280800 Il-1 binding proteins
11/17/2011	CA2800311A1 Anti-fgfr2 antibodies
11/17/2011	CA2799227A1 Extracorporeal devices and methods of treating complications of pregnancy
11/17/2011	CA2799217A1 Recombinantly produced antibodies targeting erbb signaling molecules and methods of use thereof for the diagnosis and treatment of disease
11/17/2011	CA2799197A1 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
11/17/2011	CA2799181A1 Ospa chimeras and use thereof in vaccines
11/17/2011	CA2799177A1 Enhanced death receptor agonists
11/17/2011	CA2799046A1 Il-1 binding proteins
11/17/2011	CA2798932A1 The n-domain of carcinoembryonic antigen and compositions, methods and uses thereof
11/17/2011	CA2798924A1 Improved methods for preparing squalene
11/17/2011	CA2798888A1 High concentration antibody formulations
11/17/2011	CA2798856A1 Immunostimulatory and vaccine compositions
11/17/2011	CA2798328A1 Yeast cell wall components and detection thereof
11/17/2011	CA2797720A1 Humanized and chimeric monoclonal antibodies to cd47
11/17/2011	CA2793545A1 Treatment methods
11/16/2011	EP2386861A2 Cross-ß structure binding compounds
11/16/2011	EP2386859A2 Diagnostic tumor markers
11/16/2011	EP2386645A2 Vector for treatment vaccine for stable and constitutive high-expression cervical cancer and recombinant lactobacillus transformed by the same
11/16/2011	EP2386577A2 Tumor-targeting monoclonal antibodies to FZD10 and uses thereof
11/16/2011	EP2386576A1 Tumor-specific recognition molecules
11/16/2011	EP2386575A2 Dual specificity antibodies and methods of making and using
11/16/2011	EP2386574A2 Polypeptide variants with altered effector function
11/16/2011	EP2386318A1 Targeted biocides
11/16/2011	EP2386317A1 Methods for treating conditions associated with MASP-2 dependent complement activation
11/16/2011	EP2386316A1 Methods for treating conditions associated with MASP-2 dependent complement activation
11/16/2011	EP2386315A1 Methods for treating conditions associated with MASP-2 dependent complement activation

1 ... 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 ... 1823